Marine Maurel
A5015446858- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Respiratory viral infections research
- COVID-19 Clinical Research Studies
- Viral Infections and Outbreaks Research
- Health disparities and outcomes
- COVID-19 and healthcare impacts
- Bacterial Infections and Vaccines
- Immune responses and vaccinations
- HIV/AIDS Research and Interventions
- COVID-19 and Mental Health
- Health, Environment, Cognitive Aging
- HIV-related health complications and treatments
- Viral gastroenteritis research and epidemiology
- Climate Change and Health Impacts
- HIV/AIDS drug development and treatment
- Air Quality and Health Impacts
- HIV, Drug Use, Sexual Risk
- Cervical Cancer and HPV Research
- COVID-19 Impact on Reproduction
- Healthcare Systems and Public Health
- Syphilis Diagnosis and Treatment
- Biological Research and Disease Studies
- Optimism, Hope, and Well-being
Centre de recherche en Epidémiologie et Santé des Populations
2021-2022
Université de Bordeaux
2021
Inserm
2020-2021
Université de Toulouse
2020-2021
Université Toulouse III - Paul Sabatier
2020-2021
Data on health inequalities related to the dynamic of SARS-CoV-2 infection in France are scarce. The aim this study was analyse association between an area-based deprivation indicator and incidence, positivity, testing rates May 2020 April 2021.We analysed data reported Système d'Information de Dépistage Populationnel surveillance system 14, 29, 2021, which records results all tests France. Residential addresses tested individuals were geocoded retrieve associated aggregated units for...
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 vaccine effectiveness (IVE) estimates two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against than A(H3N2): EU-PC 53% (95% CI: 41 63) 30% −3 54) A(H3N2). For EU-H, these were 44% 30 55) 14% −32 43), respectively.
Background Between October 2022 and January 2023, influenza A(H1N1)pdm09, A(H3N2) B/Victoria viruses circulated in Europe with different (sub)types dominating areas. Aim To provide interim 2022/23 vaccine effectiveness (VE) estimates from six European studies, covering 16 countries primary care, emergency care hospital inpatient settings. Methods All studies used the test-negative design, but differences other study characteristics, such as data sources, patient selection, case definitions...
Abstract Background Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season Europe, followed by higher circulation of A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated vaccine effectiveness (VE) using a multicentre test‐negative study. Materials Methods Primary practitioners collected information specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, (sub)type clade, age group, target group time since...
Abstract Background In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure vaccine effectiveness (VE). Methods Primary practitioners collected information on patients presenting with acute respiratory infection. Cases were A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls virus negative. We calculated VE using logistic regression, adjusting for site, age, sex, onset date, presence of chronic...
In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. a multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September and January 2024. Using test-negative case–control design, VE in the target group for overall by time since vaccination. We included 1057 cases 4397 controls. Vaccine was 40 % (95 CI: 26–53 %) overall, 48 31–61 among those vaccinated < 6...
Background Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim We aimed to estimate primary series (PS) and first booster VE symptomatic BA.1/BA.2 infection investigate potential biases. Methods This test-negative multicentre study tested care patients with acute respiratory symptoms for the BA.1/BA.2-dominant period. estimated PS among adults adolescents (PS only) all products combined Comirnaty alone,...
Abstract Background Integrase strand transfer inhibitors (INSTIs) are increasingly used in patients living with HIV due to their safety, effectiveness and high genetic barrier. However, an association weight gain has recently been suggested several cases of diabetes mellitus have reported raltegravir dolutegravir. The long-time metabolic impact these recent molecules remains unclear. Objectives To assess if INSTI as a third agent is statistically associated new-onset compared NNRTI or PI....
Within influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022-23 VEBIS European multicentre study end-of-season data to evaluate whether definition affected IVE estimates.
Importance In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) inform vaccination campaigns. Objective To estimate vaccines administered in autumn winter 2022 2023 against symptomatic infection (with all circulating viruses XBB lineage particular) among people aged 60 years older Europe, compare different CVE approaches across exposed reference groups used. Design, Setting, Participants This...
ABSTRACT We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at primary care level. VE adjusted by site, age, sex, chronic conditions and onset date. included 220 cases 1733 controls. The was 48% (95% CI: 12–71), 23% −11–48) 5% −92–56) those with symptom 1–5, 6–11, 12 weeks after vaccination, respectively. provided...
We examined the mediating role of friends smoking in association between depressive symptoms and daily/weekly cigarette from adolescence into adulthood.Data were drawn Nicotine Dependence In Teens study (NDIT, Canada) Avon Longitudinal Study Parents Children (ALSPAC, UK) studies. Three age groups investigated NDIT: 13-14 (n = 1189), 15-16 1107), 17-18 1075), one ALSPAC 4482, 18-21). Multivariable mediation models decomposed total effect (TE) on a natural direct (NDE) indirect (NIE) through...
Background: Between October 2022 and January 2023, there has been diverse circulation of influenza A(H1N1)pdm09, A(H3N2) B/Victoria viruses in Europe. Aim: To provide interim 2022/23 vaccine effectiveness (VE) estimates from six European studies, covering 16 countries primary care, emergency care hospital inpatient settings.Methods: All studies used the test-negative design, although differences other study characteristics existed, e.g. data sources, patient selection, case definitions...
Influenza A(H3N2) viruses dominated early in the 2022–23 influenza season Europe, followed by higher circulation of A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated vaccine effectiveness (VE) using a multicentre test-negative study. Primary practitioners collected information specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, (sub)type clade, age group, target group time since vaccination, logistic regression....
Background: In 2021–22, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure vaccine effectiveness (VE). Methods: Primary practitioners collected information on patients presenting with acute respiratory infection. Cases were A(H3N2) or A(H1N1)pdm09 RT-PCR positive and controls virus negative. We calculated VE using logistic regression, adjusting for site, age, sex, onset date, presence of chronic conditions. Results:...
<h3>Background</h3> In the context of Covid-19 pandemic, several factors such as age, chronic disease or obesity have been associated with adverse outcomes and mortality from Covid-19. However, social distribution infection among men women was largely neglected in France, mainly due to a lack data. The aim this study is describe analyse risk relation sex, influence other factors, specifically occupation, association. <h3>Methods</h3> We used data citizen science initiative 'Baromètre...